Venus Concept Stock Trades Higher After Lifting FY21 Sales Outlook
Venus Concept Inc’s (NASDAQ:VERO) Q2 sales increased 52% Y/Y to $25.8 million, beating the consensus of $24.26 million. The increase…
Recap: Venus Concept Q2 Earnings
Shares of Venus Concept (NASDAQ:VERO) rose 15.3% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 102.56% year over year to $0.01, which beat the estimate of ($0.12).
Venus Concept Sees FY21 Sales $102M-$107M vs $103.24M Est.
Assuming no significant and persistent resurgence of COVID-19 and related lockdown measures in key markets that would negatively impact the Company's customer base, and based on strong pipeline activity, the Company
Venus Concept Q2 EPS $0.01 Beats $(0.12) Estimate, Sales $25.80M Beat $24.26M Estimate
Venus Concept (NASDAQ:VERO) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.12) by 108.33 percent. This is a 102.56 percent increase over losses of $(0.39) per share from
Earnings Scheduled For August 13, 2021
Companies Reporting Before The Bell
• Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million.
24 Stocks Moving in Wednday’s Pre-Market Session
Gainers
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) rose 43.6% to $2.93 in pre-market trading after a 13G filing from Ra Capital showed a 7.5% stake in the company.
Venus Concept Shares Move Higher; Co Publishes Clinical Trial Titled ‘Mechanical Coring to Achieve Directional Skin Tightening’ To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT04910945